China's drug regulator has approved clinical trials for an experimental mpox vaccine developed by Sinopharm (HKG: 1099).
Until recently, Danish vaccine maker Bavarian Nordic (OMX: BAVA) was the only company to offer a vaccine for the infectious disease, branded as Jynneos. In August, a rival jab dubbed ACAM2000 and developed by Emergent BioSolutions (NYSE: EBS) was also approved in the USA.
Sinopharm’s option was jointly developed by a division of the Chinese Center for Disease Control and Prevention, together with a subsidiary of the company, the Beijing Institute of Biological Products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze